Why the study?
Do intravenous PDE inhibitors piroximone and enoximone improve circulatory responses in male patients undergoing elective aortocoronary bypass grafting?
Do intravenous PDE inhibitors piroximone and enoximone improve circulatory responses in male patients undergoing elective aortocoronary bypass grafting?
Both piroximone and enoximone exhibit significant arterial and venous vasodilatory properties during cardiopulmonary bypass, with enoximone producing more pronounced and prolonged microcirculatory improvements.
No takes yet. Share an insight, caveat, or question.
Supports PDE inhibitor use to blunt MAP rise during bypass; confirms vasodilatory effects in cardiac surgical patients.
Boldt et al. (1993) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: